Picture of BLIS Technologies logo

BLT BLIS Technologies Share Price

0.000.00%
nz flag iconLast trade - 00:00
HealthcareAdventurousMicro CapContrarian

Momentum

Relative Strength (%)
1m-13.79%
3m-27.31%
6m-38.31%
1yr-55.57%
Volume Change (%)
10d/3m+39.63%
Price vs... (%)
52w High-50%
50d MA-11.14%
200d MA-29.11%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-2.82%
Return on Equity-3.21%
Operating Margin-2.74%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of BLIS Technologies EPS forecast chart

Profile Summary

Blis Technologies Limited is a New Zealand-based manufacturer of advanced probiotic strains. The Company’s principal activity is developing healthcare products based on strains of bacteria that produce bacteriocin activity for sale in New Zealand and overseas. It delivers probiotic solutions for specific health targets, including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. Its probiotic portfolio includes BLIS K12, BLIS M18 and BLIS Q24. It sells ingredients and finishes goods to manufacturers and wholesale customers. The BLIS K12 (Streptococcus salivarius K12) is a probiotic to support the mouth and throat. The BLIS M18 (Streptococcus salivarius M18) is a probiotic to support teeth and gum health. The BLIS Q24 balances and restores the skin microbiome, restoring its natural health, clarity and radiance. The Company’s products are sold throughout New Zealand and in Australia, Asia, Europe and the United States.

Directors

Last Annual
March 31st, 2023
Last Interim
September 30th, 2023
Incorporated
June 20th, 2000
Public Since
July 30th, 2001
No. of Employees
10
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
nz flag iconNew Zealand Stock Exchange
Shares in Issue
1,273,801,599

BLT Share Price Performance

Upcoming Events for BLT

Full Year 2024 BLIS Technologies Ltd Earnings Release

BLIS Technologies Ltd Annual Shareholders Meeting

Similar to BLT

Picture of AFT Pharmaceuticals logo

AFT Pharmaceuticals

nz flag iconNew Zealand Stock Exchange

Picture of EBOS logo

EBOS

nz flag iconNew Zealand Stock Exchange

Picture of Rua Bioscience logo

Rua Bioscience

nz flag iconNew Zealand Stock Exchange

FAQ